This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Probi Past Earnings Performance

Past criteria checks 1/6

Probi's earnings have been declining at an average annual rate of -32.7%, while the Biotechs industry saw earnings declining at 2.5% annually. Revenues have been declining at an average rate of 1.6% per year. Probi's return on equity is 0.8%, and it has net margins of 1.7%.

Key information

-32.74%

Earnings growth rate

-32.74%

EPS growth rate

Biotechs Industry Growth	0.71%
Revenue growth rate	-1.58%
Return on equity	0.80%
Net Margin	1.73%
Next Earnings Update	28 Feb 2025

Recent past performance updates

Analysis Article • Jul 24

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

A lackluster earnings announcement from Probi AB (publ) ( STO:PROB ) last week didn't sink the stock price. We think...

Recent updates

Analysis Article • Nov 21

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

The Probi AB (publ) ( STO:PROB ) share price has done very well over the last month, posting an excellent gain of 31...

Analysis Article • Jul 24

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

A lackluster earnings announcement from Probi AB (publ) ( STO:PROB ) last week didn't sink the stock price. We think...

Analysis Article • Jun 26

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) ( STO:PROB ) shareholders have had their patience rewarded with a 43% share price jump in the last...

Analysis Article • Sep 08

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Probi AB (publ...

Analysis Article • Mar 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Probi (STO:PROB) has had a rough month with its share price down 1.8%. It seems that the market might have completely...

Analysis Article • Feb 15

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Analysis Article • Jan 29

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

If you want to know who really controls Probi AB (publ) ( STO:PROB ), then you'll have to look at the makeup of its...

Analysis Article • Jan 11

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Does the January share price for Probi AB (publ) ( STO:PROB ) reflect what it's really worth? Today, we will estimate...

Revenue & Expenses Breakdown

How Probi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:PROB Revenue, expenses and earnings (SEK Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	630	11	170	36
30 Jun 24	643	14	170	37
31 Mar 24	608	-1	174	37
31 Dec 23	628	17	172	36
30 Sep 23	616	14	176	39
30 Jun 23	605	20	174	38
31 Mar 23	635	46	168	39
31 Dec 22	618	41	167	38
30 Sep 22	644	73	159	36
30 Jun 22	658	79	155	38
31 Mar 22	642	75	147	37
31 Dec 21	658	83	143	37
30 Sep 21	673	79	140	39
30 Jun 21	709	93	144	37
31 Mar 21	731	105	144	37
31 Dec 20	717	93	150	36
30 Sep 20	699	97	149	33
30 Jun 20	645	85	144	32
31 Mar 20	646	88	153	33
31 Dec 19	626	86	151	31
30 Sep 19	623	84	154	30
30 Jun 19	650	90	157	31
31 Mar 19	623	81	150	31
31 Dec 18	604	76	147	33
30 Sep 18	561	53	139	35
30 Jun 18	525	34	139	34
31 Mar 18	544	29	139	35
31 Dec 17	612	69	138	37
30 Sep 17	687	98	147	41
30 Jun 17	643	117	138	41
31 Mar 17	544	118	122	40
31 Dec 16	443	102	103	37
30 Sep 16	286	74	53	54
30 Jun 16	248	60	49	48
31 Mar 16	234	54	53	38
31 Dec 15	216	49	57	31
30 Sep 15	220	52	82	0
30 Jun 15	205	46	76	0
31 Mar 15	178	39	67	0
31 Dec 14	135	22	60	0
30 Sep 14	122	19	58	0
30 Jun 14	109	16	56	0
31 Mar 14	104	15	55	0

Quality Earnings: PROB has high quality earnings.

Growing Profit Margin: PROB's current net profit margins (1.7%) are lower than last year (2.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PROB's earnings have declined by 32.7% per year over the past 5 years.

Accelerating Growth: PROB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PROB had negative earnings growth (-20.4%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).

Return on Equity

High ROE: PROB's Return on Equity (0.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/14 18:59
End of Day Share Price	2025/02/12 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Probi AB (publ) is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jakob Lembke	ABG Sundal Collier Sponsored
null null	ABG Sundal Collier Sponsored

This company listing is no longer active

Probi Past Earnings Performance

Past criteria checks 1/6

Key information

Recent past performance updates

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Recent updates

New major risk - Revenue and earnings growth

Symrise AG (XTRA:SY1) completed the acquisition of remaining 30.35% stake in Probi AB (publ) (OM:PROB) from Fourth Swedish National Pension Fund (AP4), Moneta Asset Management and others.

Probi AB (publ)(OM:PROB) dropped from OMX Nordic All-Share Index

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

New major risk - Share price stability

Now 27% overvalued after recent price rise

Probi AB (publ) Announces CFO Changes

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi AB (Publ) Launches Probi Sense

New minor risk - Share price stability

Now 21% undervalued

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Now 25% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021

Third quarter 2021 earnings released: EPS kr1.62 (vs kr2.91 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Should You Be Adding Probi (STO:PROB) To Your Watchlist Today?

Estimating The Intrinsic Value Of Probi AB (publ) (STO:PROB)

Consensus EPS estimates fall to kr8.37

Second quarter 2021 earnings released: EPS kr1.39 (vs kr2.37 in 2Q 2020)

Investor sentiment improved over the past week

Is Now The Time To Put Probi (STO:PROB) On Your Watchlist?